Molecular imaging employing 18 [F] FDG-PET/CT enables in-vivo visualization, characterisation and measurement of biological process in tumour at the molecular and cellular level. In oncology, this approach can be directly applied as translational biomarkers of disease progression. In this article, the improved roles of FDG as an in-vivo glycolytic marker which reflect biological changes across in-vitro cellular environment are discussed
AbstractTreatment decisions in oncology are increasingly guided by information on the biologic chara...
Treatment decisions in oncology are increasingly guided by information on the biologic characteristi...
The aim of this study was to investigate the difference in the rates of FDG uptake between malignant...
Molecular imaging employing (18)[F]FDG-PET/CT enables in-vivo visualization, characterisation and me...
The accurate depiction of both biologic and anatomic profiles of tumors has long been a challenge in...
Positron Emission Tomography (PET) is a functional imaging modality widely used in clinical oncology...
olecular imaging in oncology is defined as the noninvasive imaging of the key molecules and molecula...
Imaging biomarkers have a potential to depict the hallmarks of cancers that characterise cancer cell...
18F-fluorodeoxyglucose (FDG) PET/CT is a pivotal imaging modality for cancer imaging, assisting diag...
Development of the positron emission tomography (PET) diagnostic radiopharmaceutical (18F) fluoro-2-...
Development of the positron emission tomography (PET) diagnostic radiopharmaceutical (18F) fluoro-2-...
Upregulated glucose metabolism in tumors and metastases can be visualized by PET using 18F‑fluoro‑2‑...
AbstractImaging biomarkers have a potential to depict the hallmarks of cancers that characterise can...
As a widely used diagnostic tool, 18F-FDG PET/CT combines anatomic imaging with functional imaging a...
The glucose analog 18F-FDG is a surrogate marker for glucose metabo-lism and the most commonly used ...
AbstractTreatment decisions in oncology are increasingly guided by information on the biologic chara...
Treatment decisions in oncology are increasingly guided by information on the biologic characteristi...
The aim of this study was to investigate the difference in the rates of FDG uptake between malignant...
Molecular imaging employing (18)[F]FDG-PET/CT enables in-vivo visualization, characterisation and me...
The accurate depiction of both biologic and anatomic profiles of tumors has long been a challenge in...
Positron Emission Tomography (PET) is a functional imaging modality widely used in clinical oncology...
olecular imaging in oncology is defined as the noninvasive imaging of the key molecules and molecula...
Imaging biomarkers have a potential to depict the hallmarks of cancers that characterise cancer cell...
18F-fluorodeoxyglucose (FDG) PET/CT is a pivotal imaging modality for cancer imaging, assisting diag...
Development of the positron emission tomography (PET) diagnostic radiopharmaceutical (18F) fluoro-2-...
Development of the positron emission tomography (PET) diagnostic radiopharmaceutical (18F) fluoro-2-...
Upregulated glucose metabolism in tumors and metastases can be visualized by PET using 18F‑fluoro‑2‑...
AbstractImaging biomarkers have a potential to depict the hallmarks of cancers that characterise can...
As a widely used diagnostic tool, 18F-FDG PET/CT combines anatomic imaging with functional imaging a...
The glucose analog 18F-FDG is a surrogate marker for glucose metabo-lism and the most commonly used ...
AbstractTreatment decisions in oncology are increasingly guided by information on the biologic chara...
Treatment decisions in oncology are increasingly guided by information on the biologic characteristi...
The aim of this study was to investigate the difference in the rates of FDG uptake between malignant...